A new biologic agent, Dupilimab, may be a possible treatment for chronic obstructive pulmonary disorder. Join host, Geoff Wall, as he evaluates the use of dupilimab in COPD with Type 2 inflammation
Type 2 inflammation is driven by eosinophils and IL-4, 5, and 11. It occurs in 20% of patients with COPD. Dupilimab was able to decrease COPD exacerbations by 50% and improve symptoms
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. PMID: 37272521.
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the different phenotypes of COPD and treatment options
2. Describe the BOREAS trial and the applicability to patients with COPD
0.05 CEU/0.5 Hr
Initial release date: 8/21/2023
Expiration date: 8/21/2024
Additional CPE details can be found here.